Antipsychotic Practice Patterns and Clinical Outcomes in Moderate-to-severe TBI (P10-7.005)
Year: 2025
Type: article
Abstract: Objective: In this study, we sought to assess the pattern of antipsychotics used for moderate-severe TBI (msTBI) and their relationship to functional outcomes. Background: msTBI may result in episodes of agitation and delirium throughout hospital stay. In managing these episodes, atypical antipsychotics are largely preferred to typical agents in a msTBI population due to their reduced side-effect burden and less deleterious effect on recovery. Design/Methods: A single-center retrospective cohort study of msTBI patients (initial GCS <14 with ICU admission) was performed (10/2022–10/2024). Patients receiving antipsychotics during hospitalization (quetiapine/olanzapine/risperidone) were compared to those who did not. Outcomes included poor outcome defined as mRS 5–6, and length-of-stay. Univariate and multivariate analyses were performed to assess relationship between variables and outcomes (significance p<0.05). Results: Of 129 included patients (median 47 years [IQR 29–67], initial GCS 8 [IQR 4–12], 42 (32.6%) were treated with antipsychotics (81.4% seroquel, mean dose 131mg daily). When compared to the no-antipsychotic cohort, those receiving antipsychotics were younger (37 [28.25–58] vs 57 [32–73], p=0.021). The antipsychotic cohort had decreased mortality (0% (0/42) vs. 33.3% (29/87), p<0.001) and increased median length of stay (24.5 vs. 13 days, p<0.001). In multiple logistic regression, age [OR 1.02, CI 1.00–1.05, p=0.023], initial GCS [OR 0.89, CI 0.80–0.98, p=0.022], blown pupils at admission [OR 3.33, CI 1.35–8.24, p=0.009], and antipsychotic use [OR 0.27, CI 0.10–0.71, p=0.008] showed significant associations with poor outcome. Conclusions: The administration of antipsychotics in msTBI patients appears to be influenced by local prescribing habits, correlating with younger age and longer hospital stays. Agitation and antipsychotic use may reflect lower severity TBI in patients that ultimately survive. Future prospective studies are needed to further elucidate the clinical endophenotypes between antipsychotic responders. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff. Disclosure: Mr. Hanna has nothing to disclose. Mr. Ramesh has nothing to disclose. Miss Joyner has received research support from National Institute of Health. Miss Joyner has received research support from UCI MIND. Dr. Darwish has nothing to disclose. Dr. Akbari has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for AZ Injury Law. The institution of Dr. Akbari has received research support from NIH. The institution of Dr. Akbari has received research support from Hamamatsu Photonics KK. Dr. Akbari has received intellectual property interests from a discovery or technology relating to health care. Dr. Stern-Nezer has nothing to disclose. Dr. Dastur has nothing to disclose. Dr. Valesky has nothing to disclose. Dr. Goodwin has nothing to disclose. Dr. Yu has nothing to disclose. The institution of Dr. Chen has received research support from Mitsubishi. Areg Grigorian has nothing to disclose. Dr. Nahmias has nothing to disclose. Dr. Chen has nothing to disclose.
Source: Neurology
Institution: University of California, Irvine
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: moderate to severe traumatic brain injury, antipsychotic use, atypical antipsychotics, olanzapine, quetiapine, risperidone, agitation, delirium, functional outcome, mortality, length of hospital stay, Glasgow Coma Scale, pupil reactivity, hospitalization, clinical practice patterns, clinical outcomes, age as confounder
Open Access status: green
OpenAlex ID: W4409237372
